Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

n-GAAP earnings are projected

to rise to approximately $7.00 per diluted share by 2011.

-- Myozyme sales are expected to be approximately $275-$285 million this

year, compared to prior guidance of $320-$330 million.

-- Non-GAAP earnings per share for the second quarter are expected to be

in the mid $0.90s, reflecting ongoing investments to drive future

growth. These include investments in the U.S. launch of Renvela(R)

(sevelamer carbonate) and the expanded European introduction of

Clolar(R) (clofarabine), as well as investments in late-stage clinical

trials-particularly the phase 3 study of alemtuzumab for multiple

sclerosis. This estimate also reflects the constraints on U.S. Myozyme

sales.

First-Quarter Product Sales

-- Within the Therapeutics business, worldwide demand for Myozyme remains

robust two years into the product's launch. First-quarter sales rose

78 percent despite the delay in U.S. approval for 2000L production

capacity. Sales increased to $67.3 million from $37.9 million in the

period a year ago, driven by the number of new patients starting

therapy. As announced, the FDA will require Genzyme to submit a BLA to

obtain U.S. commercial approval for Myozyme produced at the 2000L

scale. The agency is expected to act on the application by the end of

this year.

-- First-quarter sales of Cerezyme(R) (imiglucerase for injection) rose 15

percent to $304.3 million, compared with $263.8 million in the previous

first quarter.

-- Sales of Fabrazyme(R) (agalsidase beta) grew 16 percent in the quarter,

rising to $116.5 million from $100.7 million in the first quarter last

year. Fabrazyme has captured more than a two thirds share of the

international market for Fabry disease treatment based on compelling

clinical dat
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) ... report "Neuroprotection - Drugs, Markets and Companies" ... describes the role of neuroprotection in acute disorders ... system as well as in chronic diseases such ... mechanisms of damage to neural tissues are similar ...
(Date:5/28/2015)... Texas (PRWEB) May 28, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... attending the World Pork Expo, June 3-5 in ... this year in a Wall Street Journal article ...
(Date:5/28/2015)... MIAMI BEACH, Fla. , May 28, 2015 /PRNewswire/ ... data supporting the anti-cancer potential of its growth hormone-releasing ... presentation at the 2015 ASCO Annual Meeting. The ... the target for Biscayne,s anti-cancer GHRH blockers, is present ... receptor status. These findings suggest that GHRH antagonists could ...
Breaking Biology Technology:Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... 2, 2011 C3i, a world leader in clinical ... newest client, XBiotech, Inc. XBiotech, located in Austin, TX, ... and has launched the first "True Human" monoclonal antibody ... pathologic inflammatory responses and is being developed to treat ...
... June 2, 2011 Morphotek®, Inc., a subsidiary of ... multi-center, phase II study of MORAb-004 for the treatment ... potentially first-in-class monoclonal antibody that specifically binds to endosialin/tumor ... its safety and therapeutic activity at two dosages. ...
... Pharmaceuticals, Inc. (NYSE Amex: AEN ), a ... diseases, announced today positive findings based on further analyses ... with near-term plans for its Alzheimer,s disease program. After ... Adeona intends to conduct another Alzheimer,s disease clinical study ...
Cached Biology Technology:C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 3Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 2Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 3Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 4Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 5Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 6
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... of the climate debate concludes that the majority of ... a vocal minority of skeptics is holding onto the ... story of current issue Chemical & Engineering News (C&EN), ... much-publicized United Nations Climate Change Conference in Copenhagen. That ...
... the deoxycytidine kinase (dCK) enzyme have defects in their ... T and B lymphocytes, the major players involved in ... UCLA,s Jonsson Comprehensive Cancer Center. The finding could ... body attacks itself, and possibly certain cancers of the ...
... large amounts of hatchery-raised young salmonids are released into ... natural production. Butthese fish generally survive poorly in the ... why: the young fish get too crowded at the ... granting 2 million euro to a Swedish/Nordic research project. ...
Cached Biology News:Enzyme necessary for development of healthy immune system 2Enzyme necessary for development of healthy immune system 3Hatchery-raised salmon too crowded 2
... Unconjugated Applications: ELISA: ... at an assay dependent dilution. WB: Use at ... concentration is determined using a whole extract of ... tested in other applications. Optimal dilutions/concentrations should ...
SHP-2 Antibody...
... Glycine Transporter 2, Neuronal (GLYT2). The antiserum ... the central nervous system. The staining pattern ... described using in situ hybridization with probes ... been described for glycinergic neurons. Preabsorption of ...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide ... LIGHT. PACKAGED UNDER INERT GAS. A potent ... dose-dependent manner (K i = 1.7 ... Soluble in EtOH or DMSO. Unstable in ...
Biology Products: